Compare · CTOR vs NVO
CTOR vs NVO
Side-by-side comparison of Citius Oncology Inc. (CTOR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTOR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 2993.2x CTOR ($63.9M).
- Over the past year, CTOR is down 51.3% and NVO is down 45.0% - NVO leads by 6.3 points.
- CTOR has been more active in the news (10 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 2 for CTOR).
- Company
- Citius Oncology Inc.
- Novo Nordisk A/S
- Price
- $0.68-7.69%
- $43.28+1.15%
- Market cap
- $63.9M
- $191.15B
- 1M return
- -19.76%
- -7.90%
- 1Y return
- -51.30%
- -45.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 10
- 8
- Recent ratings
- 2
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CTOR
- SEC Form EFFECT filed by Citius Oncology Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Citius Oncology Inc.
- SEC Form 424B3 filed by Citius Oncology Inc.
- Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
- SEC Form DEF 14C filed by Citius Oncology Inc.
- SEC Form S-3 filed by Citius Oncology Inc.
- Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
- SEC Form 424B3 filed by Citius Oncology Inc.
- SEC Form PRE 14C filed by Citius Oncology Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care